Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Liver Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Leucovorin 22Fluorouracil 22Paclitaxel 21Gemcitabine 21Docetaxel 21Capecitabine 21Irinotecan 16Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × Ramucirumab × Clear all
NCT00917384 2019-09-25

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Eli Lilly and Company

Phase 3 Completed
355 enrolled 16 charts
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡